bioAffinity Technologies, Inc. (BIAF) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -242.0%, revenue growth 19.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $6.16M |
| Revenue (TTM) | $0.0B |
| Net Margin | -242.0% |
| Return on Equity | -402.9% |
| Operating Margin (TTM) | -209.8% |
| Debt / Equity | 0.07 |
| Current Ratio | 1.44 |
| Net Debt / EBITDA | 0.6 |
| Interest Coverage | -276.1 |
| Revenue Growth (YoY) | 19.0% |
| EPS Growth (YoY) | 276.5% |
| FCF Growth (YoY) | 23.7% |
| Price / Book | 1.14 |
| Price / Sales | 0.73 |
| FCF Yield | -269.9% |
| Altman Z-Score | -10.48 (distress) |
| Industry P/E (Business Services) | 28.3 |
| Sector P/E (Technology) | 31.8 |
BIAF overview · BIAF earnings · BIAF KPIs · BIAF documents · BIAF ownership · BIAF peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.